Closing Bangladesh's Mental-Health Treatment Gap: Build Care Into Primary Health, Not Around It

Diagnosis

Bangladesh treats almost none of the people who need mental-health care. The curated assessment puts adult prevalence at roughly 17 percent, while the treatment gap runs above 90 percent against the WHO mhGAP benchmark. In plain terms: for every ten adults living with a mental-health condition, more than nine receive no treatment at all. This is not a problem at the margin of the health system. It is a structural failure of where and how care is delivered.

The gap persists because the system assumes mental-health care must come from psychiatrists and specialist institutions, which are too few and too concentrated to reach most of the population. The conditions in question are common, often manageable with basic protocols, and overwhelmingly present in the same primary care settings people already visit for physical complaints. Treating this as a specialist problem guarantees the gap stays above 90 percent. Treating it as a primary-care problem is the only path that scales. The lead body is the Directorate General of Health Services (DGHS), the operator of the public primary-care network through which any solution must run.

Recommended actions

1. Integrate mhGAP protocols into primary care. Owner: DGHS. Mechanism: a DGHS operational circular adopting the WHO mhGAP intervention guide as the standard of care at upazila health complexes and union-level facilities, with screening for common conditions added to routine outpatient flow. Observable signal: a rising count of mhGAP screenings recorded in the DHIS2/HMIS reporting that DGHS already operates.
2. Train and certify non-specialist providers. Owner: DGHS (in-service training wing). Mechanism: a standing mhGAP training and supervision programme for existing medical officers, nurses, and community health workers, so frontline staff can identify, treat the routine majority, and refer the severe minority. Observable signal: the share of trained-and-certified frontline staff per upazila climbing over successive quarters.
3. Guarantee essential psychotropic supply. Owner: DGHS (essential drugs and logistics). Mechanism: add the core mhGAP medicines to the essential drug list pushed through the existing primary-care procurement and distribution chain, so a diagnosis can be matched with treatment on the spot. Observable signal: stock-out days for these medicines falling toward zero at upazila stores.
4. Build a referral spine and supervision loop. Owner: DGHS, with district hospitals as the referral tier. Mechanism: a written referral pathway from union and upazila level upward, plus periodic specialist supervision visits so quality holds as volume rises. Observable signal: documented referrals flowing in both directions and supervision visits logged on schedule.
5. Extend reach through community and environmental-health touchpoints. Owner: DGHS, supported by the Department of Public Health Engineering (DPHE). Mechanism: use DPHE's community-level field presence as an additional channel for awareness and case-finding where DGHS facilities are thin, routing identified cases into the primary-care pathway. Observable signal: a rising share of treated cases originating from community referral rather than walk-in alone.

Sequencing (first 12 months)

Start with the circular and the training programme: nothing else functions until frontline staff are authorized and equipped to act. In parallel, fix the drug supply, because a screening protocol without medicines produces diagnoses no one can treat and erodes trust fast. Once protocols, trained staff, and stock are in place at a first set of upazilas, stand up the referral spine and supervision loop, then extend community case-finding through DPHE. This sequence unlocks measurable movement in the treatment gap within the first year by converting facilities people already use into points of care.

Risks and constraints

The binding constraint is fiscal and human-resource scarcity, not ambition: trained staff, supervision time, and a reliable drug supply all compete for limited primary-care budget. Stigma suppresses demand even where supply exists, so case-finding must be active, not passive. The political risk is reverting to a specialist, institution-centric model that looks prestigious but cannot touch a gap above 90 percent. DGHS must hold the line on a primary-care-first design.

Bottom line

A treatment gap above 90 percent against roughly 17 percent prevalence is a delivery-model failure, not a specialist-shortage footnote, and DGHS can close it only by building basic mental-health care into the primary-care network people already use. The first year should buy authorization, trained staff, and reliable medicines at the front line, because every later gain depends on those three being in place.